Lerzam (Lercanidipine Hydrochloride)

Lercanidipine is a calcium channel blocker used to manage arterial hypertension and related blood‑pressure disorders.

• Hypertension: Lowers systolic and diastolic blood pressure, helping patients reach target levels.
• Essential hypertension: Provides sustained blood‑pressure control in primary hypertension.
• Isolated systolic hypertension: Reduces elevated systolic pressure, particularly in older adults.

• Lercanidipine selectively blocks L‑type calcium channels in vascular smooth muscle, inhibiting calcium influx. This causes relaxation of arterial smooth muscle, leading to vasodilation, decreased peripheral vascular resistance, and ultimately a reduction in systemic blood pressure without significant effect on cardiac contractility.

Lercanidipine may cause adverse reactions that vary in frequency and severity.

Common Side Effects

• Headache: Mild to moderate pain often occurring after dose initiation.
• Flushing: Warm sensation and redness of the skin, especially on the face.
• Peripheral edema: Swelling of the ankles or lower legs.
• Dizziness: Light‑headedness, particularly when standing quickly.
• Tachycardia: Increased heart rate, usually transient.
• Fatigue: General feeling of tiredness.

Serious or Rare Side Effects

• Severe hypotension: Marked drop in blood pressure leading to fainting.
• Myocardial infarction: Rare occurrence of heart attack.
• Angioedema: Swelling of the face, lips, or throat requiring urgent care.
• Hepatic injury: Uncommon liver enzyme elevations.
• Severe allergic reaction: Rash, itching, or anaphylaxis.
• Cardiac arrhythmia: Irregular heart rhythm in susceptible individuals.

Before prescribing Lercanidipine, clinicians should consider several safety measures.

• Monitor blood pressure: Check regularly to avoid excessive hypotension.
• Assess hepatic function: Use caution in patients with liver impairment.
• Review concomitant antihypertensives: Adjust doses to prevent additive effects.
• Avoid abrupt discontinuation: Taper gradually to reduce rebound hypertension.
• Evaluate CYP3A4 inhibitors: Dose may need adjustment when strong inhibitors are co‑administered.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lercanidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): May increase plasma levels and risk of hypotension.
• Grapefruit juice: Potentiates drug exposure, leading to excessive blood‑pressure lowering.
• Other potent vasodilators: Combined use can cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): May reduce effectiveness.

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Can blunt antihypertensive response.
• Diuretics: May enhance diuretic‑induced electrolyte changes.
• Beta‑blockers: Requires careful blood‑pressure monitoring.